Consequences of long-term use of fezolinetant

Fezolinetant is a new oral selective neurokinin receptor 3 (NK3R) antagonist, mainly used to relieve the symptoms of hot flashes in menopausal women. Its mechanism of action is to stabilize body temperature and relieve hot flashes by regulating neurokinin signals in the hypothalamic temperature regulation center. Due to its relatively precise mechanism, fizonatant is considered safer than traditional hormone replacement therapy in clinical application, and is especially suitable for patients who cannot use estrogen or have hormone-related contraindications. However, long-term use still requires attention to potential risks and adverse effects.

First, long-term use of fezonatant may have certain effects on liver function. Clinical data show that a small number of patients experience elevated transaminases during medication. Therefore, it is recommended to conduct baseline liver function tests before treatment and regularly monitor liver enzyme levels during treatment, especially in the first three months after starting medication and when symptoms of discomfort occur. Secondly, fezonatant may affect the function of the nervous system. Some patients may experience mild headaches, insomnia or mood swings after long-term use of the drug. This is related to the drug acting on the neural signaling pathways of the hypothalamus, but the symptoms are usually mild and controllable.

In addition, fezonatant may affect markers of blood and kidney function. Although uncommon, long-term use still requires monitoring of hematological indicators under the guidance of a physician to prevent potential abnormalities. Use with caution or avoid long-term use in patients with a history of severe renal impairment or cirrhosis. At the same time, fezonatant is contraindicated in pregnant and lactating women because its safety to the fetus or infant has not yet been determined.

In general, long-term use of fezonatant is relatively safe in most patients, but liver function, blood indicators, and potential neurological reactions still need to be closely monitored, and the dose should be adjusted or discontinued in a timely manner if abnormalities occur.

Reference materials:https://www.veozah.com/